LIC MF Healthcare Fund Regular Growth
EquitySector - HealthcareVery High Risk
Regular
NAV (06-Sep-24)
Returns (Since Inception)
Fund Overview
Fund Size
₹69 Cr
Expense Ratio
2.44%
ISIN
INF397L01LG2
Minimum SIP
₹500
Exit Load
1.00%
Inception Date
28 Feb 2019
About this fund
As of 06-Sep-24, it has a Net Asset Value (NAV) of ₹29.35, Assets Under Management (AUM) of 69.18 Crores, and an expense ratio of 2.44%.
- LIC MF Healthcare Fund Regular Growth has given a CAGR return of 21.53% since inception.
- The fund's asset allocation comprises around 97.54% in equities, 0.00% in debts, and 2.46% in cash & cash equivalents.
- You can start investing in LIC MF Healthcare Fund Regular Growth with a SIP of ₹500 or a Lumpsum investment of ₹5000.
Performance against Category Average
In this section, we compare the returns of the scheme with the category average over various periods. Periods for which the fund has outperformed its category average are marked in green, otherwise red.
1 Year
+52.47%
+54.79% (Cat Avg.)
3 Years
+13.49%
+18.09% (Cat Avg.)
5 Years
+24.15%
+29.12% (Cat Avg.)
Since Inception
+21.53%
— (Cat Avg.)
Portfolio Summaryas of 31st August 2024
| Equity | ₹67.48 Cr | 97.54% |
| Others | ₹1.7 Cr | 2.46% |
Top Holdings
All Holdings
Equity
Debt & Others
| Name | Type  | Amount | Holdings |
|---|---|---|---|
| Sun Pharmaceuticals Industries Ltd | Equity | ₹8.09 Cr | 11.29% |
| Piramal Pharma Ltd | Equity | ₹4.81 Cr | 6.71% |
| Artemis Medicare Services Ltd Ordinary Shares | Equity | ₹4.58 Cr | 6.39% |
| Torrent Pharmaceuticals Ltd | Equity | ₹4.32 Cr | 6.03% |
| Glenmark Pharmaceuticals Ltd | Equity | ₹4.03 Cr | 5.63% |
| Cipla Ltd | Equity | ₹3.8 Cr | 5.30% |
| Mankind Pharma Ltd | Equity | ₹3.53 Cr | 4.93% |
| J.B. Chemicals & Pharmaceuticals Ltd | Equity | ₹3.23 Cr | 4.51% |
| Abbott India Ltd | Equity | ₹3.1 Cr | 4.32% |
| Alkem Laboratories Ltd | Equity | ₹2.98 Cr | 4.16% |
| Ipca Laboratories Ltd | Equity | ₹2.97 Cr | 4.14% |
| Zydus Lifesciences Ltd | Equity | ₹2.94 Cr | 4.10% |
| Divi's Laboratories Ltd | Equity | ₹2.83 Cr | 3.95% |
| Global Health Ltd | Equity | ₹2.68 Cr | 3.74% |
| Apollo Hospitals Enterprise Ltd | Equity | ₹2.49 Cr | 3.47% |
| Treps | Cash - Repurchase Agreement | ₹2.36 Cr | 3.30% |
| Suven Pharmaceuticals Ltd | Equity | ₹2.23 Cr | 3.12% |
| Dr Reddy's Laboratories Ltd | Equity | ₹2.09 Cr | 2.91% |
| Laurus Labs Ltd | Equity | ₹2 Cr | 2.79% |
| Navin Fluorine International Ltd | Equity | ₹1.73 Cr | 2.41% |
| Metropolis Healthcare Ltd | Equity | ₹1.67 Cr | 2.33% |
| Syngene International Ltd | Equity | ₹1.38 Cr | 1.93% |
| Yatharth Hospital and Trauma Care Services Ltd | Equity | ₹0.99 Cr | 1.38% |
| Neuland Laboratories Limited | Equity | ₹0.72 Cr | 1.00% |
| Neogen Chemicals Ltd | Equity | ₹0.72 Cr | 1.00% |
| Net Receivables / (Payables) | Cash | ₹-0.6 Cr | 0.84% |
Allocation By Market Cap (Equity)
Large Cap Stocks
37.88%
Mid Cap Stocks
24.28%
Small Cap Stocks
34.38%
Other Allocation
Equity Sector
Debt & Others
| Sector | Amount | Holdings |
|---|---|---|
| Healthcare | ₹66.72 Cr | 93.13% |
| Basic Materials | ₹2.44 Cr | 3.41% |
Risk & Performance Ratios
Standard Deviation
This fund
15.69%
Cat. avg.
15.96%
Lower the better
Sharpe Ratio
This fund
0.52
Cat. avg.
0.79
Higher the better
Sortino Ratio
This fund
--
Cat. avg.
1.44
Higher the better
Fund Managers
Karan Doshi
Since July 2023
Additional Scheme Detailsas of 31st August 2024
ISIN | INF397L01LG2 | Expense Ratio | 2.44% | Exit Load | 1.00% | Fund Size | ₹69 Cr | Age | 28 Feb 2019 | Lumpsum Minimum | ₹5,000 | Fund Status | Open Ended Investment Company | Benchmark | BSE Healthcare TR INR |
Investment Objective
To seek to generate long-term capital growth from an actively managed portfolio primarily of Equity and Equity Related Securities. Scheme shall invest in Indian equities,foreign equities and related instruments and debt securities.
Tax Treatment
Capital Gains Taxation:
- If units are sold after 1 year from the date of investment: Gains up to INR 1.25 lakh in a financial year are exempt from tax. Any gains exceeding INR 1.25 lakh are taxed at a rate of 12.5%.
- If units are sold within 1 year from the date of investment: The entire amount of gain is taxed at a rate of 20%.
- Holding the units: No tax is applicable as long as you continue to hold the units.
Dividend Taxation:
Dividends are added to the investor’s income and taxed according to their respective tax slabs. Additionally, if an investors dividend income exceeds INR 5,000 in a financial year, the fund house deducts a 10% Tax Deducted at Source (TDS) before distributing the dividend.
Note: As per the Income Tax Budget 2024, mutual funds are subject to capital gains taxation, which includes surcharge and cess based on prevailing income tax rules and the investor’s income. Taxation applies only to realised gains, not notional gains. Please consult your tax advisors to determine the implications or consequences of your investments in such securities.
Similar Sector - Healthcare Funds
| Fund name | Expense Ratio | Exit Load | Fund size | 1Y  |
|---|---|---|---|---|
| Motilal Oswal S&P BSE Healthcare ETF Very High Risk | 0.2% | - | ₹14.97 Cr | 55.2% |
| Aditya Birla Sun Life Pharma & Healthcare Fund Direct Growth Very High Risk | 1.0% | 1.0% | ₹791.70 Cr | 56.3% |
| Aditya Birla Sun Life Pharma & Healthcare Fund Regular Growth Very High Risk | 2.3% | 1.0% | ₹791.70 Cr | 54.1% |
| Aditya Birla Sun Life Nifty Healthcare ETF Very High Risk | 0.2% | - | ₹31.78 Cr | 52.5% |
| ITI Pharma and Healthcare Fund Direct Growth Very High Risk | 0.4% | 1.0% | ₹183.39 Cr | 55.6% |
| ITI Pharma and Healthcare Fund Regular Growth Very High Risk | 2.3% | 1.0% | ₹183.39 Cr | 52.7% |
| Mirae Asset Healthcare Fund Direct Growth Very High Risk | 0.5% | 1.0% | ₹2560.38 Cr | 53.4% |
| Mirae Asset Healthcare Fund Regular Growth Very High Risk | 1.9% | 1.0% | ₹2560.38 Cr | 51.2% |
| Nippon India Nifty Pharma ETF Very High Risk | 0.2% | - | ₹798.61 Cr | 52.8% |
| Axis NIFTY Healthcare ETF Very High Risk | 0.3% | - | ₹18.87 Cr | 51.4% |
About the AMC
LIC Mutual Fund
Total AUM
₹1,609 Cr
Address
4th Floor, Industrial Assurance Building, Mumbai, 400 020
Other Funds by LIC Mutual Fund
| Fund name | Expense Ratio | Exit Load | Fund size | 1Y |
|---|---|---|---|---|
| LIC MF Gold ETF FOF Direct Growth High Risk | 0.3% | 1.0% | ₹54.40 Cr | 21.1% |
| LIC MF Equity Savings Fund Direct Growth Moderately High risk | 1.0% | 1.0% | ₹19.38 Cr | 16.1% |
| LIC MF Nifty Next 50 Index Fund Direct Growth Very High Risk | 0.3% | 0.0% | ₹95.83 Cr | 63.7% |
| LIC MF Focused 30 Equity Direct Growth Very High Risk | 1.6% | 1.0% | ₹151.43 Cr | 31.6% |
| LIC MF Long Term Value Fund Direct Growth Very High Risk | 1.6% | 1.0% | ₹123.47 Cr | 43.3% |
| LIC MF Healthcare Fund Direct Growth Very High Risk | 1.2% | 1.0% | ₹69.18 Cr | 54.4% |
| LIC MF Small Cap Fund Direct Growth Very High Risk | 1.5% | 1.0% | ₹318.40 Cr | 53.5% |
| LIC MF Midcap Fund Direct Growth Very High Risk | 1.6% | 1.0% | ₹319.71 Cr | 51.3% |
| LIC MF Dividend Yield Fund Direct Growth Very High Risk | 1.4% | 1.0% | ₹330.46 Cr | 60.2% |
Risk Level
Your principal amount will be at Very High Risk
Unlock Expert Insights!
Related Articles
Still got questions?
We're here to help.
What is the current NAV of LIC MF Healthcare Fund Regular Growth?
What are the returns of LIC MF Healthcare Fund Regular Growth?
What is the portfolio composition of LIC MF Healthcare Fund Regular Growth?
Who manages the LIC MF Healthcare Fund Regular Growth?
- Karan Doshi
Dezerv Investments Private Limited is a Portfolio Manager with SEBI Registration no. INP000007377 and an Investment Manager to Category - I AIF-VCF-Angel Fund with SEBI Registration no. IN/AIF1/22-23/1066.
Mutual Fund distribution services are offered through Dezerv Distribution Services Pvt Limited, a wholly owned subsidiary with AMFI Registration No.: ARN -248439. **Mutual fund investments are subject to market risks, read all scheme related documents carefully.** Terms and conditions of the website are applicable. Privacy policy of the website is applicable.